Skip to main content
BTAI logo
BTAI
(NASDAQ)
BioXcel Therapeutics, Inc.
$1.11-- (--)
Loading... - Market loading

BioXcel Therapeutics (BTAI) Stock Price & Financial Analysis

BioXcel Therapeutics Stock Price Chart

Price Chart

Loading chart...

Financial Metrics & Key Statistics

Fundamental metrics, valuation ratios, and profitability indicators

Day's Range$1.08 - $1.15
52-Week High$8.08
52-Week Low$1.01
Open$1.12
Volume741.42K
Average Volume (3M)701.83K
Market Cap13.31M
Shares Outstanding12.21M
Price to Sales (P/S)20.73
Price to Book (P/B)-0.14
EV/EBITDA-1.80
Revenue (TTM)642.00K
Net Income (TTM)-69.90M
Free Cash Flow (TTM)-57.62M
EPS (TTM)$-7.15
Profit Margin-10887.38%
Operating Margin-7829.75%
50-Day MA$1.15
200-Day MA$1.87
52-Week Change-37.99%
Annual Dividend$0.00
Dividend Yield0.00%

Frequently Asked Questions About BioXcel Therapeutics

What is the current stock price for BTAI?

As of the latest trading session, BTAI stock trades at $1.11. The 52-week range is $1.01–$8.08, with a day range of $1.08–$1.15.

What is the P/E ratio for BTAI?

The P/E ratio (Price-to-Earnings) for BTAI is shown in the Key Statistics section. This valuation metric helps compare BioXcel Therapeutics, Inc. to industry peers.

Does BTAI pay dividends?

BioXcel Therapeutics does not currently pay a regular dividend. The company reinvests earnings into growth and operations. Check the Dividends tab for historical dividend information.

What do analysts recommend for BTAI?

Based on 2 analysts, the consensus for BTAI is Buy. The average 12-month price target is $NaN, representing a NaN% downside from the current price.

What is the market cap of BTAI?

BioXcel Therapeutics's market capitalization is $13.6M, classifying it as a micro-cap company. BioXcel Therapeutics operates in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry.